Cancer cocktail trial halted early – what went wrong?

NCT ID NCT02959437

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated early, meaning the results are incomplete and no clear conclusions can be drawn about its effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine, pembrolizumab, and epacadostat
What this could lead to: If successful, this combination might offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer head and neck squamous cell carcinoma melanoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES METASTATIC CANCER SOLID TUMORS

Contacts and locations

Locations

Churchill Hospital

Oxford, Ox37le, United Kingdom
City of Hope National Medical Center

Duarte, California, 91010, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Sarah Cannon

Nashville, Tennessee, 37203, United States
The University of Chicago

Chicago, Illinois, 60637, United States
Univ De Navarra

Pamplona, 31008, Spain
University College London Hospitals (Uclh)

London, W1t7ha, United Kingdom
University of California San Diego

La Jolla, California, 92093, United States
University of Pennsylvania Health System

Philadelphia, Pennsylvania, 19014, United States
University of Washington

Seattle, Washington, 98109, United States
Vall D Hebron Univ

Barcelona, 08035, Spain
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.